ABSTRACT. A murine model for short-chain acyl-coenzyme A dehydrogenase (SCAD) deficiency has been identified and characterized in BALBJcByJ mice. These mice have undetectable SCAD activity, severe organic aciduria; excreting ethylmalonic and methylsuccinic acids and Nbutyrylglycine, and develop a fatty liver upon fasting or dietary fat challenge. The mutant mice develop hypoglycemia after an 18-h fast, and have elevated urinary and muscle butyrylcarnitine concentrations. Most of these findings parallel those of human disorders associated with SCAD deficiency and other P-oxidation defects. This mouse model presents important opportunities to investigate the biology of mammalian fatty acid metabolism and the related human diseases. (Pediatr Res 25:38-43, 1989) Abbreviations SCAD, short-chain acyl-CoA dehydrogenase MCAD, medium-chain acyl-CoA dehydrogenase MCT, medium-chain triglycerides Deficiency of SCAD has been described recently in humans (1-4). The most severe form of this disorder is characterized by patients with episodes of metabolic acidosis, nonketotic hypoglycemia, and short-chain dicarboxylic aciduria. The clinical outcomes range from normalcy to unexpected death in homozygotes. Lately, sudden infant death syndrome and Reye's-like syndrome have been linked to defects in P-oxidation of fatty acids (5-7). Other recent studies have demonstrated that a secondary carnitine deficiency associated with the organic acidemia appears involved in the pathogenesis of the episodic events of these disorders (1, 4, 8) . Overall, these diseases appear complex.
ABSTRACT. A murine model for short-chain acyl-coenzyme A dehydrogenase (SCAD) deficiency has been identified and characterized in BALBJcByJ mice. These mice have undetectable SCAD activity, severe organic aciduria; excreting ethylmalonic and methylsuccinic acids and Nbutyrylglycine, and develop a fatty liver upon fasting or dietary fat challenge. The mutant mice develop hypoglycemia after an 18-h fast, and have elevated urinary and muscle butyrylcarnitine concentrations. Most of these findings parallel those of human disorders associated with SCAD deficiency and other P-oxidation defects. This mouse model presents important opportunities to investigate the biology of mammalian fatty acid metabolism and the related human diseases. Deficiency of SCAD has been described recently in humans (1) (2) (3) (4) . The most severe form of this disorder is characterized by patients with episodes of metabolic acidosis, nonketotic hypoglycemia, and short-chain dicarboxylic aciduria. The clinical outcomes range from normalcy to unexpected death in homozygotes. Lately, sudden infant death syndrome and Reye's-like syndrome have been linked to defects in P-oxidation of fatty acids (5) (6) (7) . Other recent studies have demonstrated that a secondary carnitine deficiency associated with the organic acidemia appears involved in the pathogenesis of the episodic events of these disorders (1, 4, 8) . Overall, these diseases appear complex.
We have a program to screen mice for inherited metabolic diseases (9) to develop models for investigating the pathogenesis and treatment of these disorders. In the course of screening mutant mice for organic acidurias using gas chromatographymass spectrometry, we discovered a subline of BALB/c mice (BALB/cByJ) that excreted unusually large concentrations of ethylmalonic and methylsuccinic acids and N-butyrylglycine. Butyryl-CoA dehydrogenase activity and electrophoretic mobility are used as a genetic marker for the Bcd-1 locus on mouse chromosome 5 (10) . Subsequently, we learned that BALB/cByJ mice were found to have no detectable butyryl-CoA dehydrogenase activity by this marker assay (10) . The null allele of these mice was designated Bcd-1" and was distinctly different from the normal activity associated with the Bcd-lb allele of BALB/cJ or BALB/cBy mice. To investigate the enzymatic defect and the resulting metabolic consequences, we performed a series of experiments using BALB/c By (Y) mice as controls and the BALB/ c ByJ (J) mutant mice.
MATERIALS AND METHODS
Mice. BALB/cBy and BALB/cByJ mice were purchased from The Jackson Laboratory, (Bar Harbor, ME) and propagated at the Baylor College of Medicine (Houston, TX). All mice were maintained on Wayne rodent food no. 8640 (Wayne Pet Food Division, Continental Grain Co., Chicago, IL) and water ad libitum. Heterozygous mice were produced by crossing a Y female with a J male.
Biochemistry. Urinary organic acids were analyzed by gas chromatography-mass spectrometry as described previously (9) . Quantitative analysis of organic acids was performed by establishing standard curves of the metabolites of interest coextracted from water with the internal standard malonic acid. Urine samples were extracted and analyzed in a similar way with final quantification of the metabolites based upon the creatinine concentration of the urine, calculated from the internal standard added to the urine as described (9) . Ethylmalonic, methylsuccinic, and succinic acids were obtained from Sigma Chemical Co., St. Louis, MO. Because a standard for quantification of Nbutyrylglycine was not available, values obtained are the succinic acid molar equivalent. Serum amino acids were analyzed as described (9) and serum glucose was determined by the toluidine blue 0 method (1 1). (Toluidine blue 0 was obtained from Eastman Kodak, Rochester, NY.) ACyl-CoA dehydrogenase assays were performed using the dye reduction assay as described previously (3) on liver mitochondria isolated as before (12) . Carnitine analysis was done using the radioenzymatic method (13, 14) to determine the free and acylcarnitines, and specific carnitine species were identified and quantified using fast-atom bombardment-mass spectrometry (1 5, 16) .
MCT challenge and fasting experiments. Two-month-old mice of both genotypes and sexes were assigned to a group to receive either MCT and fast for 10 h or fast only. Nonfasting urine samples were collected before treatment, and MCT was given per us at 150 mg/kg, 3 x every 4 h, and the final samples of urine, blood, and tissues were obtained 2 h after the last dose. In a different experiment, mice of each genotype were fasted for 18 h with collection of urine, blood, and tissues for histopathology. All mice were killed humanely by a lethal dose of pentobarbital and exsanguination.
Carnitine loading studies. Mice of both genotypes, 2 mo old, were given a single dose of L-carnitine 100 mg/kg per os or no treatment and maintained on food and water for 10 h. Mice were then killed humanely by a lethal dose of pentobarbital and exsanguination. At the end of the experiment, urine and blood were collected and quadriceps muscle was obtained and frozen in liquid nitrogen.
RESULTS
Urine organic acid analysis by gas chromatography-mass spectrometry showed a marked organic aciduria in the J mice compared to the normal pattern seen in the Y control mice (Fig. 1) . The overall results indicate markedly increased concentrations [% (SD) pmol/mg creatinine] of ethylmalonic 55.3 (90.2) and methylsuccinic acids 10.3 (1 8.3) and N-butyrylglycine 178 (254) in nonfasting urine samples of six J mice; of these compounds only butyrylglycine in small amounts was detected in some control Y mice. This urine metabolite pattern would indicate a possible block in short-chain fatty acid oxidation. This was confirmed by enzymology of liver mitochondria, as described in Table 1 . Overall butyryl-CoA dehydrogenation, which is catalyzed by both SCAD and MCAD, in the J mice averaged only 44% as compared to the Y control mice. By inhibiting MCAD activity with monospecific MCAD antiserum, the SCAD specific activity in the J mice is undetectable and heterozygotes have intermediate activity.
In the MCT challenge experiment, there were no clinical differences observed among the four groups. Results of that experiment (Table 2) showed that before the fasting period the J mice (n = 4) had markedly elevated urinary concentrations of ethylmalonic acid, methylsuccinic acid, and N-butyrylglycine, compared to only a small amount of N-butyrylglycine detected in the control Y mice (n = 3). After the fasting period, with or without the MCT challenge, the Y controls had undetectable quantities of all three compounds, but the J mice had markedly elevated concentrations of ethylmalonic acid, methylsuccinic acid, and N-butyrylglycine. There were no major differences between the mutant mice groups whether or not they received MCT. The metabolite concentrations were lower in this experiment than in the random urines collected and analyzed from different mice described earlier. We currently do not understand the reason for this, except that urinary metabolites in general can vary widely in concentration. The serum glycine concentrations were significantly lower 0, < 0.025 by Student's t-test) in the J mice comparing the like treatment groups (see Table 2 ). There were no differences in any other amino acid concentrations in any of the groups (data not shown). Also, there were no differences between the groups for serum glucose as a result of these treatments. Whether or not they received MCT oil, all J mice had fatty livers. This was confirmed by histopathology. No other lesions were seen, including examination of skeletal muscle.
In marked contrast, after an 18-h fast in a different experiment, the mean serum glucose value of the J mice is 46% of the value of control mice (see Table 2 ). This is markedly different from the similar values seen among the four groups during the MCT experiment (10-h fast). By visual inspection, we also noticed friable, fatty livers in all the J mice, with normal-appearing livers in the Y controls after the fasting period. Histopathology demonstrated marked fatty change in the fasted J mice as compared to minimal changes seen in the controls (see Fig. 2) .
In a final set of experiments, we examined the carnitine status of these mice, because human patients with the related disorders are often carnitine deficient ( l , 4 ) when ill and excrete diagnostic acylcarnitines in their urine (7, 8, (13) (14) (15) (16) especially when dosed with carnitine. As shown in Table 3 , the J mice that received no carnitine, had slightly lower plasma and urine total carnitine. After the carnitine load, they excreted large amounts of butyrylcarnitine (Fig. 3) , which was detected in only trace amounts in the urine of the control group. Similarly, muscle carnitine analysis showed 9-fold higher concentrations of butyrylcarnitine in mutants than in the controls (see Table 3 ), which is significantly different 0, < 0.005), by Student's t-test. DISCUSSION We have described and demonstrated SCAD deficiency in BALB/cByJ mice. Metabolically, SCAD is involved in dehydrogenation of short-chain (C4-6) acyl-CoA in p-oxidation of fatty acids. When SCAD is deficient, abnormal metabolites accumulate. Ethylmalonic acid is probably produced from the intrami-40 WOOD ET AL. * The Y control mice are BALB/cBy, and the J mice with the marked organic aciduria are BALB/cByJ. Heterozygotes were produced by crossing a male J with a female Y. The mice analyzed here were I mo old, and mitochondria were isolated from the liver. The antiserum used was rabbit anti-pig kidney MCAD and is added for preincubation with mitochondria1 protein for 5 min at 37°C before substrates are added to start the reaction. Values given are mean and (SD). Serum glycine Serum glucose (wmol/liter) (mg/dl) *All mice were 2 mo old, both sexes were tested. Medium-chain triglyceride oil was given per os at 150 mg/kg/dose, given three times every 4 h, and the final samples were collected 2 h after the last dose. The mice were fasted for 10 h. In all the samples analyzed, a trace of adipic acid was detected in 2 SCAD-deficient mice, none in any of the controls, and no suberic, sebacic, 3-hydroxybutyric, or glutaric acids were detected in any of the samples. In a different experiment, the mice were fasted only for 18 h and serum was collected for glucose assay. All values given are mean and (SD). ND, none detected.
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tochondrial accumulation of butyryl-CoA, which is carboxylated by propionyl-CoA carboxylase to form ethylmalonyl-CoA, then hydrolyzed to ethymalonic acid (17) . N-butyrylglycine is formed by glycine conjugation of excess butyryl-CoA (18) . Also, we have detected methylsuccinic acid in the urines of the SCAD-deficient mice, as found in the human patients. It is most likely generated from ethylmalonyl-CoA via formation of methylsuccinyl-CoA by methylmalonyl-CoA mutase (17) . The recent finding of octanoylcarnitine (7, 14) and demonstrated MCAD deficiency in human cases of sudden infant death and Reye's syndromes implicates deficiency of MCAD and possibly the other acyl-CoA dehydrogenases in their pathogenesis. The SCAD-deficient mice have many biochemical and pathologic features like those of the human patients described with SCAD deficiency and many similarities to the P-oxidation enzyme deficiencies in general. These mice have a marked ethylmalonic and methylsuccinic aciduria as described in the human patients, but in addition they have high concentrations of Nbutyrylglycine, not detected in some of the reported patients (3, 4) . This is likely attributable to the well characterized differences between rodents and humans in glycine conjugation of various CoA derivative substrates, particularly butyryl-CoA (18) . Rodents more readily produce butyrylglycine than primates for reasons that remain unclear. However, the production of butyrylglycine as an alternative pathway to eliminate excess butyrylCoA is analogous to the production of suberylglycine and hexanoylglycine in MCAD deficiency (19) and isovalerylglycine in isovaleryl-CoA dehydrogenase deficiency (20) of humans. As discussed for isovaleric acidemia (20) , glycine conjugation is a critical alternative pathway and is probably a major factor in determining the clinical severity of the disease. We hypothesize this may be an important mechanism to explain the relative resistance of these mice to acute clinical disease. We speculate the lower serum glycine in the mutant mice (as shown in Table  2 ) may result from the major urinary loss of butyrylglycine in the urine.
Additionally, these mice develop severe fatty liver and hypoglycemia upon prolonged fasting of 18 h. Surprisingly, they remain clinically normal at this point. Another possible factor concerning the relative resistance to acute disease in the mice is that they have been maintained on standard rodent chow with a 5% wt/wt fat content, which is relatively low compared to the average growing child's diet. As demonstrated earlier, the mutant mice do not appear to have a systemic carnitine deficiency, although there was marked elevation of urinary and muscle butyrylcarnitine in the SCAD-deficient mice compared to controls. Overall, we believe this mouse model will be very useful to delineate several pathogenetic mechanisms of &oxidation defi-4 1 Fig. 2 . Liver sections from a control Y (left) and J mutant mouse (right) were stained with oil-red-0, demonstrating the prominent fatty change in the mutant as compared to minimal changes in the control after an 18-h fast. * Mice in this experiment were given no treatment or a single dose of L-carnitine (100 mg/kg) per os. Blood, urine, and muscle samples were collected 10 h after treatment. Carnitines were assayed by t radioenzymatic assay or $ high-resolution fast-atom bombardment assay. Values given are mean and (SD).
ciency diseases, and it will be useful to understand the mecha-model for any of the human P-oxidation enzyme deficiencies or nisms of what appears presently to be a relative resistance to organic acidemias, and it should be useful for investigating the acute clinical disease in the mouse compared to humans. We metabolism, pathogenesis, and treatment of human disorders of speculate that the ability readily to glycine conjugate butyryl-P-oxidation and related diseases. CoA and perhaps spare intramitochondrial carnitine concentrations may be important events protecting against acute disease. Fig. 3 . Fast-atom bombardment-mass spectrometry (FAB-MS) analysis of urinary acylcarnitines. Examples shown are of a control Y mouse (top) and an affected J (bottom) mouse after an L-carnitine dose. Note prominent butyrylcarnitine peak (246) and N-butyrylglycine (160) peak in the affected mouse urine compared to the control. Free carnitine (176) and acetylcarnitine (218) are the expected normal acylcarnitines as seen in the control urine. Quantitative studies using FAB-MS, as illustrated above, on these mouse urines showed the following concentrations (~mol/mg creatinine): controls (n = 2) N-butyrylcarnitine 0.406-0.290 and acetylcarnitine (n = 3) 11.3-22.5; affected J mice N-butyrylcarnitine (n = 2) 0.967-13.4 and acetylcarnitine (n = 2) 6.98-39.2. The specific acylcarnitines described here are components of the total acylcarnitine value given in Table 3 .
